Articles tagged with: Stem Cell Mobilization
Press Releases»
Enrollment to cease immediately; topline data anticipated in H1 2021
Tel Aviv, Israel (Press Release) – BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a planned interim analysis of the ongoing GENESIS Phase 3 trial of motixafortide for stem cell mobilization (SCM) in multiple myeloma patients.
At a meeting of the study's independent Data Monitoring Committee (DMC), a planned interim analysis of the study's primary endpoint was conducted independently by the DMC. Based on the statistically significant evidence favoring treatment with motixafortide, the DMC issued a recommendation to the Company that patient …
Press Releases»
Interim analysis in GENESIS to be completed in next few months
Tel Aviv, Israel (Press Release) – BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that a sufficient number of patients (~65% of the original planned sample size) have been enrolled in the ongoing GENESIS Phase 3 trial to allow for an interim efficacy analysis to take place in the second half of 2020. This ongoing registrational study is investigating motixafortide (BL-8040) for the mobilization of hematopoietic stem cells (HSCs) for autologous transplantation in patients with multiple myeloma. If the primary endpoint is met at the …
Press Releases»
Data from first lead-in patient cohort prompts Data Monitoring Committee to recommend early continuation to randomized placebo-controlled part 2 of trial
Tel Aviv, Israel (Press Release) – BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today positive results from the lead-in period of the GENESIS trial, a double-blind, placebo-controlled Phase 3 trial comparing BL-8040 in combination with granulocyte colony-stimulating factor (G-CSF), to G-CSF alone, for the mobilization of hematopoietic stem cells (HSCs) used for autologous transplantation in multiple myeloma patients.
The open-label, single-arm, lead-in period of the study was designed to include up to 30 patients, with Data Monitoring Committee (DMC) review after completion of …
Opinion»

In September 2015, after three months of induction with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (Decadron), my IgA heavy chain M-spike had fallen from 6.5 g/dL (65 g/L) to zero. My doctor felt that the time was right to get onto the next phase of treatment – a stem cell transplant.
I remember being apprehensive, but actually quite excited at the same time, as this procedure seemed to be the door to a real chance of remission and – with luck – many years of good health …
News»

How has your week been, myeloma world?
Summer definitely is here at Myeloma Morning Headquarters. We had temperatures yesterday and today that rival those normally seen in early August.
We're not exactly sure how we feel about this development.
As for myeloma-related news, we have a lot of ground to cover.
We have one new myeloma research study that we summarize at length. It's about a difficult subject, namely, the impact of early relapse on the overall survival of multiple myeloma patients. It's a difficult subject because, not surprisingly, early relapse continues …
News»

Good morning, myeloma world.
We've got a lot of new myeloma-related research to cover today, so we'll get right down to business.
The first two studies we will review are related to autologous (own) stem cell transplantation.
One study looks at whether myeloma cells make their way into the infusion of a patient's own stem cells that a patient gets during the autologous transplant process. The study finds that, in some cases, myeloma cells do make it into the stem cell infusion, and when this happens, it could – again, could – …